Paper36052238
Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy.
Yang Z and 11 others. Front Oncol, 2022. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy. Papers, record 36052238. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36052238
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29993120 | Extent of lymph node dissection in patients with gallbladder cancer. | Br J Surg | 2018 | https://conductscience.org/library/papers/29993120 | PubMed |
| 2 | 33593763 | Protocol for a gallbladder cancer registry study in China: the Chinese Research Group of Gallbladder Cancer (CRGGC) study. | BMJ Open | 2021 | https://conductscience.org/library/papers/33593763 | PubMed |
| 3 | 33055359 | Puzzle and Challenge in Routine Extrahepatic Bile Duct Resection for Advanced Gallbladder Carcinoma. | Gut Liver | 2020 | https://conductscience.org/library/papers/33055359 | PubMed |
| 4 | 34900698 | Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study. | Front Oncol | 2021 | https://conductscience.org/library/papers/34900698 | PubMed |
| 5 | 35346072 | Examination of the characteristics of long-term survivors among patients with gallbladder cancer with liver metastasis who underwent surgical treatment: a retrospective multicenter study (ACRoS1406). | BMC Gastroenterol | 2022 | https://conductscience.org/library/papers/35346072 | PubMed |
| 6 | 30178032 | Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial. | JAMA Oncol | 2018 | https://conductscience.org/library/papers/30178032 | PubMed |
| 7 | 29292472 | Gallbladder Cancer: Complete Resection after Second Line Treatment in Stage IV Disease. | J Gastrointest Cancer | 2019 | https://conductscience.org/library/papers/29292472 | PubMed |
| 8 | 34676166 | Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review. | Front Oncol | 2021 | https://conductscience.org/library/papers/34676166 | PubMed |
| 9 | 26643880 | Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. | Gastric Cancer | 2016 | https://conductscience.org/library/papers/26643880 | PubMed |
| 10 | 34532118 | Preoperative serum fibrinogen as a valuable predictor in the nomogram predicting overall survival of postoperative patients with gallbladder cancer. | J Gastrointest Oncol | 2021 | https://conductscience.org/library/papers/34532118 | PubMed |
| 11 | 19406039 | NCCN clinical practice guidelines in oncology: hepatobiliary cancers. | J Natl Compr Canc Netw | 2009 | https://conductscience.org/library/papers/19406039 | PubMed |
| 12 | 32945922 | Locally advanced gallbladder cancer: a review of the criteria and role of imaging. | Abdom Radiol (NY) | 2021 | https://conductscience.org/library/papers/32945922 | PubMed |
| 13 | 19652971 | Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. | Cancer Chemother Pharmacol | 2010 | https://conductscience.org/library/papers/19652971 | PubMed |
| 14 | 32878417 | [Analysis of treatment modalities and prognosis of patients with gallbladder cancer in China from 2010 to 2017]. | Zhonghua Wai Ke Za Zhi | 2020 | https://conductscience.org/library/papers/32878417 | PubMed |
| 15 | 31950882 | Trends of gallbladder cancer incidence, mortality, and diagnostic approach in urban Shanghai between 1973 and 2009. | Tumori | 2020 | https://conductscience.org/library/papers/31950882 | PubMed |
| 16 | 30611225 | Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin. | BMC Cancer | 2019 | https://conductscience.org/library/papers/30611225 | PubMed |
| 17 | 29227344 | Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. | Ann Surg | 2019 | https://conductscience.org/library/papers/29227344 | PubMed |
| 18 | 33505902 | Development and Validation of a Nomogram for Predicting Survival in Gallbladder Cancer Patients With Recurrence After Surgery. | Front Oncol | 2020 | https://conductscience.org/library/papers/33505902 | PubMed |
| 19 | 31825009 | Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection. | Ann Hepatobiliary Pancreat Surg | 2019 | https://conductscience.org/library/papers/31825009 | PubMed |
| 20 | 33028805 | Overview of current targeted therapy in gallbladder cancer. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/33028805 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42649595 | Efficacy and Safety of First-Line Chemotherapy With Gemcitabine Plus Nab-Paclitaxel in Unresectable Gallbladder Cancer. | Cancer Med | 2026 | https://conductscience.org/library/papers/42649595 | PubMed |
| 42477458 | Splicing-mediated control of hnRNPD isoform switching by SRSF2 drives PD-L1-dependent immune evasion in gallbladder cancer. | Oncogene | 2026 | https://conductscience.org/library/papers/42477458 | PubMed |
| 42324334 | Association of surgical extent with survival in locally advanced gallbladder cancer based on propensity score matching. | Sci Rep | 2026 | https://conductscience.org/library/papers/42324334 | PubMed |
| 41820390 | Alkaloids from Evodia rutaecarpa inhibit the occurrence and development of gallbladder cancer in vivo and in vitro. | Sci Rep | 2026 | https://conductscience.org/library/papers/41820390 | PubMed |
| 40696595 | Predictive and prognostic models and visualizations of distant metastasis in gallbladder cancer. | Medicine (Baltimore) | 2025 | https://conductscience.org/library/papers/40696595 | PubMed |
| 40670935 | An end-to-end interpretable machine-learning-based framework for early-stage diagnosis of gallbladder cancer using multi-modality medical data. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40670935 | PubMed |
| 40485726 | Neoadjuvant radiotherapy combined with targeted and immune therapies achieves a pathological complete response in borderline resectable gallbladder cancer: a case report and literature review. | Front Oncol | 2025 | https://conductscience.org/library/papers/40485726 | PubMed |
| 39655073 | Efficacy of neoadjuvant therapy and lymph node dissection in advanced gallbladder cancer without distant metastases: a SEER database analysis. | Front Oncol | 2024 | https://conductscience.org/library/papers/39655073 | PubMed |
| 39606221 | Comparison of treatment models for single primary advanced gallbladder cancer. | Front Immunol | 2024 | https://conductscience.org/library/papers/39606221 | PubMed |
| 39436624 | A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin. | Clin J Gastroenterol | 2025 | https://conductscience.org/library/papers/39436624 | PubMed |
| 39105433 | Prognostic Impact of Neoadjuvant Chemotherapy in Localized or Locoregionally Advanced Gallbladder Cancer: A Population-Based and Propensity Score Matched SEER Analysis. | Cancer Control | 2024 | https://conductscience.org/library/papers/39105433 | PubMed |
| 39064241 | Risk Factors and Prognostic Factors in GBC. | J Clin Med | 2024 | https://conductscience.org/library/papers/39064241 | PubMed |
| 38398143 | ANLN Promotes the Proliferation and Migration of Gallbladder Cancer Cells via STRA6-Mediated Activation of PI3K/AKT Signaling. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38398143 | PubMed |
| 38123314 | PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer. | BMJ Case Rep | 2023 | https://conductscience.org/library/papers/38123314 | PubMed |
| 37927929 | Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer. | Ann Gastroenterol Surg | 2023 | https://conductscience.org/library/papers/37927929 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CEACAM3 | 1084 | PubTator's text mining | https://conductscience.org/library/genes/1084 | NCBI Gene |
| MUC16 | 94025 | PubTator's text mining | https://conductscience.org/library/genes/94025 | NCBI Gene |
| TENM1 | 10178 | PubTator's text mining | https://conductscience.org/library/genes/10178 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36052238
GET https://conductscience.org/api/papers/v1/36052238/references?page=2